Developments Publication supports scientific rationale for Palvella’s QTORIN in DSAP Palvella Therapeutics (NASDAQ: PVLA) announced that Clinical and Experimental Dermatology has published a peer-reviewed systematic review synthesizing clinical evidence on off-label topical statin use in porokeratosis... February 2, 2026